Campo DC | Valor | Idioma |
dc.contributor.author | Ramos, Juan Carlos | - |
dc.contributor.author | Ruiz Junior., Phillip | - |
dc.contributor.author | Ratner, Lee | - |
dc.contributor.author | Reis, Isildinha M. | - |
dc.contributor.author | Brites, Carlos | - |
dc.contributor.author | Pedroso, Celia | - |
dc.contributor.author | Byrne Junior, Gerald E. | - |
dc.contributor.author | Toomey, Ngoc L. | - |
dc.contributor.author | Andela, Valentine | - |
dc.contributor.author | Harhaj, Edward W. | - |
dc.contributor.author | Lossos, Izidore S. | - |
dc.contributor.author | Harrington Junior, William J. | - |
dc.creator | Ramos, Juan Carlos | - |
dc.creator | Ruiz Junior., Phillip | - |
dc.creator | Ratner, Lee | - |
dc.creator | Reis, Isildinha M. | - |
dc.creator | Brites, Carlos | - |
dc.creator | Pedroso, Celia | - |
dc.creator | Byrne Junior, Gerald E. | - |
dc.creator | Toomey, Ngoc L. | - |
dc.creator | Andela, Valentine | - |
dc.creator | Harhaj, Edward W. | - |
dc.creator | Lossos, Izidore S. | - |
dc.creator | Harrington Junior, William J. | - |
dc.date.accessioned | 2014-09-09T15:58:20Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | http://repositorio.ufba.br/ri/handle/ri/15977 | - |
dc.description | Texto completo: acesso restrito. p. 3060-3068 | pt_BR |
dc.description.abstract | Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy. Most ATLL patients fare poorly with conventional chemotherapy; however, antiviral therapy with zidovudine (AZT) and interferon alpha (IFN-α) has produced long-term clinical remissions. We studied primary ATLL tumors and identified molecular features linked to sensitivity and resistance to antiviral therapy. Enhanced expression of the proto-oncogene c-Rel was noted in 9 of 27 tumors. Resistant tumors exhibited c-Rel (6 of 10; 60%) more often than did sensitive variants (1 of 9; 11%). This finding was independent of the disease form. Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF-4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax. In contrast, tumors in complete responders did not express c-Rel or IRF-4. Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy. The expression of nuclear c-Rel and IRF-4 occurs in the absence of Tax in primary ATLL and is associated with antiviral resistance. These molecular features may help guide treatment. AZT and IFN-α is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely. | pt_BR |
dc.language.iso | en | pt_BR |
dc.rights | Acesso Aberto | pt_BR |
dc.source | http://dx.doi.org/10.1182/blood-2006-07-036368 | pt_BR |
dc.title | IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma | pt_BR |
dc.title.alternative | Blood | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.identifier.number | v. 109, n. 7 | pt_BR |
dc.embargo.liftdate | 10000-01-01 | - |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina)
|